Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The company utilizes a proprietary structure-based drug discovery platform to design selective inhibitors aimed at critical cancer targets, with a primary focus on oncology, specifically gynecological cancers. The company's lead product candidate is azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor currently in late-stage clinical development for the treatment of Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Zentalis is actively advancing its clinical pipeline through multiple trials, including the DENALI study, and is preparing for confirmatory Phase 3 trials.